Biomarin Pharmaceutical (BMRN): Most Undervalued Stocks to Buy and Hold for 2 Years
BioMarin reported Q1 2026 revenue of $766 million on May 4 and raised full-year 2026 guidance to $3.825–$3.925 billion, about 20% year-over-year growth, citing the Amicus Therapeutics acquisition and added products (GALAFOLD, POMBILITI + OPFOLDA). The company also cited FDA approval of PALYNZIQ for adolescents, an sNDA for VOXZOGO, and pipeline updates. BioMarin said it secured ~$3.7 billion in non-convertible debt and had $221 million operating cash flow.
How this was made
The 30-second read
Why it matters
For traders, the actionable signal is the raised 2026 revenue guidance range and the stated funding plan for the Amicus deal, alongside FDA approval/submission items that can affect perceived probability-weighted pipeline value.
Market read
Company-specific guidance raise plus regulatory/pipeline updates can re-rate expectations, but the article’s listicle framing reduces incremental trading edge.
What to watch
Debt-funded acquisition (~$3.7B) could pressure risk metrics if commercial uptake or pipeline milestones underperform versus the guidance trajectory.
Background
The article summarizes BioMarin’s Q1 2026 results (reported May 4) and ties them to the Amicus acquisition and recent FDA/pipeline milestones.
Ticker impact
BioMarin raised full-year 2026 revenue guidance to $3.825–$3.925B after Q1 results and the Amicus acquisition, plus new product additions (GALAFOLD, POMBILITI/OPFOLDA).
Bias toward upside/valuation support if investors view the guidance raise and approvals as de-risking growth; near-term volatility possible around later Phase 3 readouts.
The article provides multiple concrete, company-specific datapoints (guidance range, acquisition funding, FDA approval/submission, pipeline progress), but it is framed as a “most undervalued” listicle, limiting incremental decision-making beyond the disclosed facts.
Market effects
Supports sentiment for rare-disease biopharma that can compound growth via acquisitions plus label expansions.
No specific regional market linkage beyond US FDA/regulatory context.
Limited; primarily US regulatory and company-specific guidance/pipeline execution.
Counterpoint
The piece is promotional (“undervalued to buy and hold”) and may overstate certainty; execution risk remains for upcoming Phase 3 readouts and integration of Amicus.
Key entities
- companyBioMarin Pharmaceutical Inc.
Raised full-year 2026 revenue guidance to $3.825–$3.925B; highlighted FDA approval of PALYNZIQ and sNDA submission for VOXZOGO; funded Amicus acquisition with ~$3.7B non-convertible debt.
